Today, 15 January 2024, we’re sharing this letter sent from a group of women with HER2-low incurable secondary breast cancer to NHS England and Daiichi Sankyo.

They’re calling on them to do everything they can to reach a deal to make Enhertu for HER2-low secondary breast cancer available on the NHS.


Dear Daiichi Sankyo and NHS England

We understand that you're currently in discussions which could result in a deal that will make trastuzumab deruxtecan (Enhertu) available on the NHS. As women living with HER2-low incurable secondary breast cancer, we wanted to write to you to stress how vital it is that you make that deal and make it as soon as possible.

Our reality is harsh. Our treatment options are limited. But Enhertu gives us the hope of more time.

Time to spend with our loved ones. Time to create memories. Time to see our children and grandchildren grow and be there for their important milestones.

However, it’s now over 3 months since it was provisionally rejected for use on the NHS in England. That’s 3 months where we’ve been left in limbo. Not knowing if it will be available when we need it is agonising.

We urgently need this agreement for Enhertu.

We all know its potential. We’re all agreed what a game-changer it is for people with our type of breast cancer. The first effective HER2-targeted treatment that gives us the chance of more time to live and more time before our cancer progresses.

Knowing this treatment exists, but is out of reach is so cruel. So please, do everything you can to make a deal. And do it as soon as possible. Give us hope for the future.

Yours sincerely,

Tracy
Jeannie
Kate W
Dr Amy
Sophie
Hannah G
Susan
Kathryn R
Sarah
Lanette
Kathryn H
Aimee
Antonia
Alison
Glynis
Jo B
Jo W
Nicola
Gina
Charlene
Sarah
Alice
Helen P
Kelly
Sharon
Hannah J
Helen S
Viv
Jackie
Julie
Christine